ArticleZeitschrift fur Rheumatologie2026
[New results from the RABBIT register on the cancer risk of patients with rheumatoid arthritis treated with Janus kinase inhibitors].
Article in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Janus kinase inhibitors (JAKis) are highly effective drugs for treating inflammatory rheumatic diseases. The randomized ORAL surveillance trial showed that patients with rheumatoid arthritis (RA) aged 50 years and older with at least 1 more cardiovascular risk factor had an increased risk of malignant diseases with the JAKi tofacitinib compared to tumor necrosis factor inhibitors; however, this result has not been replicated in subsequent studies. An analysis of the German RABBIT register now revealed an overall slightly increased cancer risk in RA patients ever treated with JAKi compared to those ever treated with biological (b) disease-modifying antirheumatic drugs (DMARDs). During or after 2285 JAKi treatment episodes and 4259 bDMARD treatment episodes, 88 and 135 malignant diseases occurred, respectively, resulting in a rate of 11.6 (95% confidence interval, CI: 9.3-14.3) events for JAKis and 8.9 (95% CI: 7.4-10.5) events for bDMARDs per 1000 patient years. The adjusted hazard ratio was 1.40 (95% CI: 1.09-1.80), which is comparable to the results from the ORAL surveillance study. Particularly affected by the observed risk increase were patients aged 60 years and older, those with high disease activity and those who had already received ≥ 3 treatments with conventional synthetic DMARDs. Other above-average affected groups included smokers, male patients and patients with an RA duration of > 10 years. When treating patients with an increased risk, clinicians should carefully consider together with them whether this observed risk outweighs the potential risks of discontinuing or withholding a highly effective treatment such as JAKis, bearing in mind that inadequate disease control is also associated with an increased risk of cancer. When in doubt, the results from RABBIT should not discourage physicians from prescribing a JAKi treatment to patients who need it. It could be a way forward to ensure that a close cancer screening is carried out for risk patients treated with JAKis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.